Overview
BridgeBio Pharma, Inc., based in the United States, operates within the biotechnology sector, focusing primarily on genetic diseases and genetically validated targets. Since its inception, the company has dedicated itself to the development of medicines aimed at treating grievous genetic diseases by leveraging advances in genetic understanding. BridgeBio engages in various key projects across its pipeline, including therapies targeting conditions such as familial adenomatous polyposis and achondroplasia. The company embraces a comprehensive approach by collaborating with academic institutions to accelerate drug discovery and development processes, aiming to translate genetic insights into clinically actionable solutions for patients suffering from severe genetic disorders.
Basic Stats
The share price of BridgeBio Pharma, Inc. as of September 4, 2025 is €44.78 / share. This is an increase of 8.58% from the prior week. The market cap (or net worth) of BridgeBio Pharma, Inc. as of September 5, 2025 is €8,560.26 MM.
The Factor Analysis chart (below right) shows a view of BridgeBio Pharma, Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 8,560.26 MM |
| EV | |
| Shares Out. | 191.16 MM |
| Earnings Date | |
| EPS (TTM) | -4.06 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | 0.18 |
| Beta | 0.68 |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | -0.98 |
| ROE | |
| ROIC | -9.71 |
| CROIC | 2.52 |
| OCROIC | -8.20 |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | 86.02 /100 |
| Profitability | 33.49 /100 |
| Quality Score | 22.92 /100 |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | 90.35 /100 |
| Analyst Sentiment | |
| Fund Sentiment | 46.80 /100 |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for BridgeBio Pharma, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2025-06-30 | Wells Fargo | Overweight | Overweight | Maintains |
| 2025-09-03 | JP Morgan | Overweight | Overweight | Maintains |
| 2025-09-03 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-04-30 | Piper Sandler | Overweight | Overweight | Maintains |
| 2025-04-30 | Scotiabank | Sector Outperform | Sector Outperform | Maintains |
| 2025-04-30 | UBS | Buy | Buy | Maintains |
| 2025-04-15 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2025-03-31 | Redburn Atlantic | Buy | Initiate | |
| 2025-03-24 | JP Morgan | Overweight | Overweight | Maintains |
| 2025-02-21 | Scotiabank | Sector Outperform | Sector Outperform | Maintains |
| 2025-02-21 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2025-02-21 | Citigroup | Buy | Buy | Maintains |
| 2025-02-13 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-02-12 | Scotiabank | Sector Outperform | Sector Outperform | Maintains |
| 2024-12-23 | Evercore ISI Group | Outperform | Outperform | Maintains |
| 2024-12-16 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-11-25 | Scotiabank | Sector Outperform | Sector Outperform | Maintains |
| 2024-11-25 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-11-25 | B of A Securities | Buy | Buy | Maintains |
| 2024-11-15 | Scotiabank | Sector Outperform | Sector Outperform | Maintains |
| 2024-10-25 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-10-17 | Leerink Partners | Outperform | Outperform | Maintains |
| 2024-10-16 | Scotiabank | Sector Outperform | Initiate | |
| 2024-10-03 | Oppenheimer | Perform | Initiate | |
| 2024-10-02 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-09-30 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-09-17 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-09-16 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-09-16 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-09-11 | B of A Securities | Buy | Buy | Maintains |
| 2024-09-09 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-09-04 | Piper Sandler | Overweight | Initiate | |
| 2024-09-03 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-08-27 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-08-22 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-08-07 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-08-07 | Evercore ISI Group | Outperform | Outperform | Maintains |
| 2024-08-05 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-07-01 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-06-25 | B of A Securities | Buy | Buy | Maintains |
| 2024-06-20 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-06-05 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-05-30 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-05-28 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-05-28 | UBS | Buy | Buy | Maintains |
| 2024-05-20 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-05-14 | Evercore ISI Group | Outperform | Initiate | |
| 2024-03-20 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-03-19 | Cantor Fitzgerald | Overweight | Overweight | Maintains |
| 2024-03-11 | Cantor Fitzgerald | Overweight | Overweight | Maintains |
| 2024-03-05 | Mizuho | Buy | Buy | Maintains |
| 2024-03-04 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-02-23 | Citigroup | Buy | Buy | Maintains |
| 2024-01-31 | BMO Capital | Market Perform | Initiate | |
| 2024-01-29 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-01-22 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2023-11-07 | Citigroup | Buy | Initiate | |
| 2023-10-24 | Cantor Fitzgerald | Overweight | Initiate | |
| 2023-08-28 | Mizuho | Buy | Buy | Reiterate |
| 2023-08-17 | JP Morgan | Overweight | Overweight | Maintains |
| 2023-08-14 | Mizuho | Buy | Buy | Maintains |
| 2023-07-18 | Goldman Sachs | Buy | Buy | Maintains |
| 2023-07-18 | Raymond James | Outperform | Outperform | Maintains |
| 2023-07-18 | Jefferies | Buy | Hold | Downgrade |
| 2023-05-08 | Mizuho | Buy | Maintains | |
| 2023-04-19 | Evercore ISI Group | Outperform | Initiate | |
| 2023-04-13 | SVB Securities | Outperform | Maintains | |
| 2023-03-07 | JP Morgan | Overweight | Maintains | |
| 2023-03-07 | Goldman Sachs | Buy | Maintains | |
| 2023-03-07 | Raymond James | Outperform | Maintains | |
| 2023-02-06 | Cowen & Co. | Outperform | Initiate | |
| 2023-01-23 | SVB Leerink | Outperform | Maintains | |
| 2022-11-18 | JP Morgan | Overweight | Maintains | |
| 2022-08-24 | Mizuho | Buy | Maintains | |
| 2022-07-26 | SVB Leerink | Outperform | Maintains | |
| 2022-05-24 | Goldman Sachs | Buy | Maintains | |
| 2022-05-06 | SVB Leerink | Outperform | Maintains | |
| 2022-03-16 | HC Wainwright & Co. | Buy | Maintains | |
| 2022-03-11 | JP Morgan | Overweight | Maintains | |
| 2022-03-09 | SVB Leerink | Outperform | Maintains | |
| 2022-03-04 | SVB Leerink | Outperform | Maintains | |
| 2021-12-28 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-12-28 | SVB Leerink | Outperform | Maintains | |
| 2021-11-19 | SVB Leerink | Outperform | Maintains | |
| 2021-10-25 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-10-04 | SVB Leerink | Outperform | Maintains | |
| 2021-09-10 | B of A Securities | Neutral | Buy | Upgrade |
| 2021-08-06 | SVB Leerink | Outperform | Maintains | |
| 2021-05-21 | UBS | Buy | Initiate | |
| 2021-05-07 | Goldman Sachs | Buy | Maintains | |
| 2021-03-23 | SVB Leerink | Outperform | Maintains | |
| 2021-03-04 | Mizuho | Buy | Maintains | |
| 2021-02-09 | Goldman Sachs | Buy | Reiterate | |
| 2021-01-11 | HC Wainwright & Co. | Buy | Maintains | |
| 2020-12-10 | HC Wainwright & Co. | Buy | Maintains | |
| 2020-12-04 | SVB Leerink | Outperform | Maintains | |
| 2020-10-12 | HC Wainwright & Co. | Buy | Maintains | |
| 2020-06-25 | B of A Securities | Neutral | Initiate | |
| 2020-05-19 | BTIG | Buy | Initiate | |
| 2020-05-14 | SVB Leerink | Outperform | Reiterate | |
| 2020-04-13 | H.C. Wainwright | Buy | Initiate | |
| 2020-03-03 | JP Morgan | Overweight | Maintains | |
| 2020-02-19 | Mizuho | Buy | Initiate | |
| 2019-07-26 | Raymond James | Outperform | Initiate | |
| 2019-07-22 | Piper Jaffray | Overweight | Initiate | |
| 2019-07-22 | BMO Capital | Outperform | Initiate | |
| 2019-07-22 | JP Morgan | Overweight | Initiate | |
| 2019-07-22 | Jefferies | Buy | Initiate | |
| 2019-07-22 | SVB Leerink | Outperform | Initiate | |
| 2019-07-22 | Goldman Sachs | Buy | Initiate | |
| 2025-07-11 | Citigroup | Buy | Buy | Maintains |
| 2025-06-17 | Wolfe Research | Outperform | Initiate | |
| 2025-08-29 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2025-06-25 | B of A Securities | Buy | Buy | Maintains |
| 2025-07-14 | Piper Sandler | Overweight | Overweight | Maintains |
| 2025-07-14 | Jefferies | Buy | Initiate | |
| 2025-08-06 | Scotiabank | Sector Outperform | Sector Outperform | Maintains |
| 2025-08-06 | Oppenheimer | Outperform | Outperform | Maintains |
| 2025-07-09 | Oppenheimer | Perform | Outperform | Upgrade |
| 2025-06-09 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2025-07-29 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2025-07-21 | Truist Securities | Buy | Initiate |
